Back to search

Article

Modified Azacitidine plus Cytarabine versus Traditional Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective and Propensity Score Matched Analysis

2026-05-04

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> Azacitidine (AZA) is a hypomethylating agent with well-known antileukemic activity. The addition of AZA to intermediate-dose Cytarabine (IDAra-c) plus idarubicin (Ida) or etoposide (Eto) in consolidation may improve outcomes in acute myeloid leukemia (AML) patients and reduce side effect. <bold>Methods</bold> We retrospectively evaluated whether adding AZA t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8e258f1b-2d51-5dfa-9768-331a08a621ce
DOI
10.21203/rs.3.rs-9409121/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Modified Azacitidine plus Cytarabine versus Traditional Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective and Propensity Score Matched AnalysisDOI 10.21203/rs.3.rs-9409121/v1
Safety and efficacy of venetoclax-azacitidine combined with low-dose idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real- world single-center experienceSemantic proximity
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Semantic proximity
Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity
Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center studySemantic proximity
A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus VenetoclaxSemantic proximity
Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.Semantic proximity
Efficacy of venetoclax and azacitidine based therapy in favorable-risk unfit acute myeloid leukemia: a real-world studySemantic proximity
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.Semantic proximity
Translational Research on Azacitidine Post- Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)Semantic proximity
Efficacy and Safety of Azacitidine Plus Low-dose Dasatinib Maintenance Therapy for Patients with Intermediate and High-risk Acute Myeloid Leukemia: A Prospective, Randomized, Phase Ⅱ Clinical TrialSemantic proximity
Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A StudySemantic proximity
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionSemantic proximity
Select a neighboring publication to make it the new centre.